Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide Phase 2 Treatment Trial in Patients with Rare Genetic Disorders of Obesity
2017-000387-14Phase 2Unknown
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of setmelanotide in obesity, sponsored by Rhythm Pharmaceuticals. Status: unknown.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on 2017-000387-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000387-14.